Portfolio Lab

Bristol Myers Squibb Co

  • Stock
  • Ticker BMY
  • ISIN US1101221083
  • NYSE

Health care · Pharmaceuticals · USA

$58.80 +0.79%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Bristol Myers Squibb Co since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

BMYGlobal equities (VT)

$10,000 grew to $14,802. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −47.7% in 07/2024, measured from the peak in 12/2022. The old peak has not been reached again yet.

1-year return
+33.7%
5-year return p.a.
+4.6%
10-year return p.a.
+4.0%
Volatility p.a.
23.5%
Largest decline
−47.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue12,34211,20112,26912,22212,50211,48912,97313,069
Gross profit7,5308,1688,8978,7878,4058,0689,2478,923
Net income722,4561,3102,2011,0872,6773,3172,162
Earnings per share0.041.200.641.080.531.311.621.05
Balance sheet
Total assets92,60392,42794,67696,88990,03886,47687,63488,772
Liabilities76,21574,97977,18778,28971,53366,37465,31565,368
Equity16,33517,38917,43518,55218,47320,06822,31923,404
Cash10,34610,87512,59915,72610,2099,5748,7229,574
Long-term debt47,60346,15744,47044,46942,85042,15242,09341,849
Cash flow
Operating cash flow4,4391,9543,9176,3111,9741,1043,3934,181
Capital expenditure-378-260-361-320-370-347-305-344
Free cash flow4,0611,6943,5565,9911,6047573,0883,837

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +27.9%, weakest 2023 at −26.2%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$1.05
30 Jul 2026$1.62
30 Apr 2026$1.31
11 Feb 2026$0.53
30 Oct 2025$1.08
31 Jul 2025$0.64
24 Apr 2025$1.20
12 Feb 2025$0.04
31 Oct 2024$0.60
26 Jul 2024$0.83
25 Apr 2024−$5.89
13 Feb 2024$0.87

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€109bn
Market cap in trading currency
$120bn
Enterprise value
$151bn
P/E
13.0
P/S
2.40
P/B
5.14
EV/Sales
3.02
EV/EBITDA
10.2
Earnings yield
7.7%
FCF yield
7.7%

Results (last four quarters)

Revenue
$50.0bn
Gross profit
$34.6bn
EBITDA
$14.8bn
Net income
$9.24bn
Earnings per share
$4.51
Revenue per share
$24.48
Revenue growth
+6.9%
Earnings growth
−1.8%

Profitability

Gross margin
69.2%
Operating margin
26.0%
Net margin
18.5%
Return on equity
44.1%
Return on assets
10.4%

Balance sheet and cash flow

Cash
$12.6bn
Cash per share
$6.15
Financial debt
$43.6bn
Debt/equity %
186
Current ratio
1.59
Book value per share
$11.45
Operating cash flow
$10.7bn
Free cash flow
$9.29bn

Dividend

Dividend yield
4.29%
Dividend (12 months)
$2.52
Yield (12 months)
4.29%
Payout ratio
56%
Ex-dividend date
2 Oct 2026

Shares and trading

Shares outstanding
2.04bn
Volume
12.4m
Avg. volume 3 months
11.0m
Relative volume
1.1

Price and technicals

Price
$58.80
1 day
+0.8%
52-week high
$68.09
52-week low
$45.94
Distance to 52-week high
−13.6%
Distance to 52-week low
+28.0%
Distance to 50-day line
−4.3%
Distance to 200-day line
−2.7%
RSI (14)
39
Volatility 1M
28.2%

Performance

1 week
−7.3%
1 month
−6.7%
3 months
−12.6%
6 months
−1.1%
YTD
+9.0%
1 year
+28.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has BMY performed since 11/2016?

$10,000 grew to $14,802 by 20 Nov 2026, which is +4.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is BMY?

Volatility was 23.5% per year, measured on monthly returns. The largest decline from a peak was −47.7%, with the low in 07/2024.

How does BMY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BMY returned +4.0% at 23.5%. The correlation of monthly returns was 0.27; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Bristol Myers Squibb Co (BMY): Return and risk